Weekly Digest – November 2025 Weekly Digest – November 2025 16 November 2025: OBI-902 has been granted Orphan Drug Designation by US FDA for the treatment of cholangiocarcinoma OBI Pharma received FDA Orphan Drug Designation for OBI-902, a TROP2-targeting ADC […]
Weekly Digest – November 2025 Weekly Digest – November 2025 18 November 2025: Sino Biopharmaceutical announces LM-350, a CDH17 ADC has received the IND approval from NMPA Sino Biopharmaceutical announced that its subsidiary LaNova Medicines received NMPA approval in China […]
Weekly Digest – November 2025 Weekly Digest – November 2025 18 November 2025: Radiopharm Theranostics receives IND approval to initiate Phase 1 therapeutic trial of RAD 402 (KLK3-mAb with Tb161) in advanced prostate cancer Radiopharm Theranostics received Bellberry Human Research […]
Weekly Digest – November 2025 Weekly Digest – November 2025 19 November 2025: TriOar signs $356 million technology transfer agreement with Celltrion TriOar entered a major partnership with Celltrion, signing a technology transfer and joint development deal for its TROCAD […]
Weekly Digest – November 2025 Weekly Digest – November 2025 17 November 2025: Daan Biotherapeutics and TriOar sign MOU for strategic collaboration on next-generation antibody-drug conjugate development Daan Biotherapeutics signed an MOU with TriOar to establish a collaborative partnership in […]
Weekly Digest – November 2025 Weekly Digest – November 2025 20 November 2025: GlycoNex announced a collaborative research agreement with Hokkaido University Hospital to support the development of its next-generation antibody-drug conjugate (ADC) GNX1021 in gastric cancer GlycoNex entered a collaborative […]
